Related Experiment Videos

Increasing chemotherapy intensity in aggressive lymphomas: a renewal?

Bertrand Coiffier

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

|June 28, 2003

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma.

International journal of environmental research and public health·2020

Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.

British journal of haematology·2019

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2019

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.

The Lancet. Haematology·2018

Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis.

The Lancet. Haematology·2018

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2018

See all related articles